These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Ifosfamide and the metabolites of side chain oxidation--excretion in urine in various pediatric therapeutic protocols]. Boos J; Welslau U; Ritter J; Blaschke G; Schellong G Klin Padiatr; 1992; 204(4):299-305. PubMed ID: 1518269 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic effects of single-push or fractionated injections or continuous infusion of oxazaphosphorines (cyclophosphamide, ifosfamide, Asta Z 7557). Klein HO; Wickramanayake PD; Christian E; Coerper C Cancer; 1984 Sep; 54(6 Suppl):1193-203. PubMed ID: 6432305 [TBL] [Abstract][Full Text] [Related]
7. Comparison of continuous infusion and bolus administration of ifosfamide in children. Boddy AV; Yule SM; Wyllie R; Price L; Pearson AD; Idle JR Eur J Cancer; 1995; 31A(5):785-90. PubMed ID: 7640054 [TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of two dosages and schedules of ifosfamide in combination with cisplatin in neo-adjuvant chemotherapy of patients with advanced (stage III-IV) head and neck squamous cell carcinoma: a phase II randomized study. Mantovani G; Ghiani M; Lai P; Maccio A; Dessi D; Succu G; Massa D; Curreli L; Mulas C; Esu S; Proto E; Cadeddu G; Tore G Oncol Rep; 1998; 5(6):1499-505. PubMed ID: 9769395 [TBL] [Abstract][Full Text] [Related]
9. A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule. Serrone L; Zeuli M; Gamucci T; Nardi M; Cognetti F Cancer Chemother Pharmacol; 2001 Mar; 47(3):206-10. PubMed ID: 11320663 [TBL] [Abstract][Full Text] [Related]
10. Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children. Boos J; Welslau U; Ritter J; Blaschke G; Schellong G Cancer Chemother Pharmacol; 1991; 28(6):455-60. PubMed ID: 1934249 [TBL] [Abstract][Full Text] [Related]
11. Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion. Silies H; Blaschke G; Hohenlöchter B; Rossi R; Jürgens H; Boos J Int J Clin Pharmacol Ther; 1998 May; 36(5):246-52. PubMed ID: 9629987 [TBL] [Abstract][Full Text] [Related]
13. Ambulatory treatment with 5 days continuous venous infusion of ifosfamide for advanced colorectal cancer: a phase II feasibility study. Focan C; Kreutz F; Levi F Anticancer Drugs; 1993 Aug; 4(4):459-62. PubMed ID: 8400348 [TBL] [Abstract][Full Text] [Related]
14. Dosing and side-effects of ifosfamide plus mesna. Brade WP; Herdrich K; Kachel-Fischer U; Araujo CE J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S164-86. PubMed ID: 1795007 [TBL] [Abstract][Full Text] [Related]
15. Ifosfamide enantiomers: pharmacokinetics in children. Prasad VK; Corlett SA; Abaasi K; Heney D; Lewis I; Chrystyn H Cancer Chemother Pharmacol; 1994; 34(5):447-9. PubMed ID: 8070015 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Willits I; Price L; Parry A; Tilby MJ; Ford D; Cholerton S; Pearson AD; Boddy AV Br J Cancer; 2005 May; 92(9):1626-35. PubMed ID: 15827549 [TBL] [Abstract][Full Text] [Related]
17. Ifosfamide combination chemotherapy in advanced breast cancer. Schmid H; Kaufmann M; Grischke EM; Bastert G Cancer Chemother Pharmacol; 1990; 26 Suppl():S71-3. PubMed ID: 2347055 [TBL] [Abstract][Full Text] [Related]
18. Poly-isoprenylated ifosfamide analogs: Preactivated antitumor agents as free formulation or nanoassemblies. Skarbek C; Delahousse J; Pioche-Durieu C; Baconnais S; Deroussent A; Renevret P; Rivard M; Desmaele D; Martens T; Le Cam E; Couvreur P; Paci A Int J Pharm; 2017 Nov; 532(2):748-756. PubMed ID: 28546071 [TBL] [Abstract][Full Text] [Related]
19. Paclitaxel by 72-hour continuous infusion followed by bolus intravenous ifosfamide or epirubicin: results of two phase I studies. Miglietta L; Marenghi C; Nizzo R; Foglia G; Ragni N; Boccardo F Oncology; 2001; 60(2):116-22. PubMed ID: 11244325 [TBL] [Abstract][Full Text] [Related]
20. Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics. Boddy AV; English M; Pearson AD; Idle JR; Skinner R Eur J Cancer; 1996 Jun; 32A(7):1179-84. PubMed ID: 8758250 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]